# Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

> **NCT02536313** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 49 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/VEL/VOX
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02536313
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-29
- **Primary completion:** 2016-03-28
- **Final completion:** 2016-06-28
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536313, "Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02536313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*